Market Trends of France Self-Monitoring Blood Glucose Devices Industry
Rising Diabetes Prevalence in France
The diabetes population in France is expected to grow by about 2.9% over the forecast period.
According to the International Diabetes Federation's reports, the prevalence of diabetes in adults in France was approximately 8.6%. Self-monitoring is a commitment that many diabetic patients make to manage their condition. The blood glucose levels help the patients and doctors modify their diet, lifestyle, insulin therapy, and medications to help their blood sugar return to normal. With newer innovations in medical technology, glucometers these days have highly sensitive strips and sensors that can detect every component of blood accurately, close to lab results.
The French health benefit basket plays an important role; diabetes is one of the 30 chronic diseases covered 100% by statutory health insurance pursuant to the ALD scheme (affections de longue durée). For those not covered under ALD, a share of the official health care tariff is paid by the patient and varies depending on the category of goods and care.
The World Health Assembly Resolution recommended the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO advising the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Test Strips Segment holds the highest market share in the current year
The test strip segment holds the highest market share of about 79.5% in the France self-monitoring blood glucose devices market in the current year.
Blood glucose test strips are small, disposable strips and are a key component of blood glucose testing. When blood is placed on the test strip, it reacts with a chemical called glucose oxidase, producing gluconic acid from the glucose in the blood. At the other end of the test strip, the meter transfers a current to the strip. The test strip has electric terminals, which allow the meter to measure the current between the terminals. The current between the terminals changes depending on the level of gluconic acid that has been produced. The blood glucose meter then uses an algorithm to work out the blood glucose level based on the difference in current.
The growth in market share of test strips is expected to be higher than that of glucose meters because of the difference in use-case frequency. The glucometer is a one-time purchase; test strips, on the other hand, are a continuous investment as a test strip needs to be disposed of after one use, causing a recurrent cost impact. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost during the same time frame,
The French healthcare system (Protection Universelle Maladie) is mostly funded by taxes and offers partial health insurance. Usually, employers sign up their employees for social contributions, and a premium is deducted from their salaries through taxes. Whenever someone requires medical attention, up to 70% of their medical costs are already covered by national health insurance, and 100% in the case of someone dealing with a long-term condition like cancer or diabetes.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated over the forecast period.
